Compare LFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | EVO |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | LFST | EVO |
|---|---|---|
| Price | $7.73 | $3.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $9.83 | $7.00 |
| AVG Volume (30 Days) | ★ 6.7M | 47.1K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,424,285,000.00 | N/A |
| Revenue This Year | $17.18 | $1.37 |
| Revenue Next Year | $14.02 | $10.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.85 | N/A |
| 52 Week Low | $3.74 | $2.31 |
| 52 Week High | $8.89 | $4.42 |
| Indicator | LFST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 56.03 |
| Support Level | $6.17 | $2.88 |
| Resistance Level | $8.09 | $3.75 |
| Average True Range (ATR) | 0.24 | 0.07 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 57.61 | 89.58 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.